Monthly application of 10 per cent moxidectin and 2.5 per cent imidacloprid spot-on to prevent relapses in generalised demodicosis: a pilot study
- PMID: 22791522
- DOI: 10.1136/vr.100843
Monthly application of 10 per cent moxidectin and 2.5 per cent imidacloprid spot-on to prevent relapses in generalised demodicosis: a pilot study
Abstract
Canine generalised demodicosis (GD) can be difficult to cure, with some dogs requiring life-long treatment. The aim of this pilot study was to evaluate the effectiveness of monthly 10 per cent moxidectin/2.5 per cent imidacloprid spot-on in maintaining long-term (12 months) clinical and parasitological remission in dogs with relapsing GD. Fourteen dogs were included: 10 with juvenile-onset GD (JOGD) and four with adult-onset GD (AOGD). All dogs had been treated previously and relapsed (1-4 times). Each dog was treated again with either milbemycin oxime 2 mg/kg or ivermectin 400 μg/kg orally once daily, until two consecutive negative skin scrapings at one-month intervals (total 4-7 months of treatment). After treatment discontinuation, 10 per cent moxidectin/2.5 per cent imidacloprid spot-on was applied monthly for 12 months. Dogs were rechecked after 1, 2, 3, 6 and 12 months, and multiple skin scrapings were taken. Twelve dogs completed the study and were clinically normal and parasitologically negative at each recheck (four dogs with AOGD and eight with JOGD). One dog died suddenly for unrelated reasons, and one dog relapsed. Results of this pilot study suggest that monthly application of 10 per cent moxidectin/2.5 per cent imidacloprid spot-on may be effective as maintenance therapy in relapsing cases of GD.
Similar articles
-
Treatment of canine generalized demodicosis with a 'spot-on' formulation containing 10% moxidectin and 2.5% imidacloprid (Advocate, Bayer Healthcare).Vet Dermatol. 2009 Oct;20(5-6):441-6. doi: 10.1111/j.1365-3164.2009.00790.x. Vet Dermatol. 2009. PMID: 20178482 Clinical Trial.
-
Treatment of canine-generalized demodicosis: a blind, randomized clinical trial comparing the efficacy of Advocate(Bayer Animal Health) with ivermectin.Vet Dermatol. 2009 Oct;20(5-6):447-55. doi: 10.1111/j.1365-3164.2009.00803.x. Vet Dermatol. 2009. PMID: 20178483 Clinical Trial.
-
Canine generalized demodicosis treated with varying doses of a 2.5% moxidectin+10% imidacloprid spot-on and oral ivermectin: parasiticidal effects and long-term treatment outcomes.Vet Parasitol. 2014 Oct 15;205(3-4):687-96. doi: 10.1016/j.vetpar.2014.08.021. Epub 2014 Sep 4. Vet Parasitol. 2014. PMID: 25262617 Clinical Trial.
-
An update on the therapy of canine demodicosis.Compend Contin Educ Vet. 2012 Apr;34(4):E1-4. Compend Contin Educ Vet. 2012. PMID: 22488596 Review.
-
New approaches to the treatment of canine demodicosis.Vet Clin North Am Small Anim Pract. 1999 Nov;29(6):1425-36. doi: 10.1016/s0195-5616(99)50136-8. Vet Clin North Am Small Anim Pract. 1999. PMID: 10563009 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources